NASDAQ:ISPC iSpecimen Q1 2026 Earnings Results & Report $0.92 -0.11 (-10.97%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.94 +0.02 (+2.29%) As of 10/16/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. iSpecimen reported Q1 2026 earnings on May 15, 2026. The company reported EPS of -$6.66, while revenue was $0.16 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeBefore Market OpensConference Call DateMay 18, 2026Conference Call7:00 AM ET iSpecimen EPS ResultsActual EPS-$6.66Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AiSpecimen Revenue ResultsActual Revenue$0.16 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsiSpecimen's Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) iSpecimen Q1 2026 Earnings FAQ Did iSpecimen beat earnings estimates for Q1 2026? iSpecimen (NASDAQ:ISPC) reported earnings of -$6.66 per share for Q1 2026. The report was announced on Friday, May 15, 2026. What was iSpecimen's revenue for Q1 2026? iSpecimen reported revenue of $0.16 million for Q1 2026. When is iSpecimen's next earnings date? iSpecimen's next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for iSpecimen on the company's earnings history page. iSpecimen Earnings HeadlinesReviewing Bullfrog AI (NASDAQ:BFRG) & iSpecimen (NASDAQ:ISPC)October 12, 2026 | americanbankingnews.comiSpecimen Shareholders Approve Key Financing and Acquisition ActionsOctober 9, 2026 | tipranks.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA DecisionSeptember 8, 2026 | rttnews.comiSpecimen to Acquire Foldlab AI Disease AnalyticsSeptember 4, 2026 | tipranks.comiSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three WeeksAugust 20, 2026 | globenewswire.comSee More iSpecimen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iSpecimen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iSpecimen and other key companies, straight to your email. Email Address About iSpecimeniSpecimen (NASDAQ:ISPC), Inc. is a healthcare technology company that operates an online marketplace connecting life sciences researchers with healthcare providers, biobanks, laboratories and other sources of human biospecimens. Its platform is designed to help researchers identify, request and obtain biological samples and related clinical data for use in drug development, diagnostics, biomarker research and other scientific applications. The company’s services support the sourcing of a broad range of specimens, including blood, tissue, bodily fluids and other human-derived samples. Through its technology platform, iSpecimen helps research organizations define sample requirements, search for suitable specimens, manage orders and coordinate fulfillment with participating providers. The company serves pharmaceutical and biotechnology companies, academic and government researchers, diagnostic developers and medical device organizations. iSpecimen was founded in 2009 and is headquartered in Lexington, Massachusetts. The company’s marketplace is intended to expand access to specimens from provider networks in the United States and other regions, while helping healthcare organizations make samples available for approved research uses. iSpecimen became a publicly traded company on the Nasdaq under the symbol ISPC in 2021.View iSpecimen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
